Do you have any concerns about incorporating gedatolisib into the treatment landscape of HR+/HER2-, PIK3CA wild-type breast cancer (VIKTORIA-1)?

VIKTORIA-1 is a clearly positive trial, but several features make it hard to know where gedatolisib fits. The main concerns are the weak fulvestrant-alone control arm, overall survival (OS) data that are not yet mature, no adequately powered comparison of the triplet versus the doublet, a high toxic...